PMS-CLARITHROMYCIN TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

现在购买

下载 产品特点 (SPC)
05-05-2022

有效成分:

CLARITHROMYCIN

可用日期:

PHARMASCIENCE INC

ATC代码:

J01FA09

INN(国际名称):

CLARITHROMYCIN

剂量:

500MG

药物剂型:

TABLET

组成:

CLARITHROMYCIN 500MG

给药途径:

ORAL

每包单位数:

100/250

处方类型:

Prescription

治疗领域:

OTHER MACROLIDES

產品總結:

Active ingredient group (AIG) number: 0123752002; AHFS:

授权状态:

APPROVED

授权日期:

2007-08-10

产品特点

                                _pms-CLARITHROMYCIN (clarithromycin) _
_Page 1 of 80_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-CLARITHROMYCIN
Clarithromycin Tablets, USP
Film-Coated Tablets, 250 mg and 500 mg, Oral
USP
Antibiotic
NOTE: WHEN USED IN COMBINATION WITH ACID ANTISECRETORY DRUGS AND OTHER
ANTIMICROBIALS FOR THE ERADICATION OF _HELICOBACTER PYLORI_, THE
PRODUCT
MONOGRAPH FOR THOSE AGENTS SHOULD BE CONSULTED.
PHARMASCIENCE INC.
6111 Royalmount Ave, Suite #100
Montréal, Québec, H4P 2T4
www.pharmascience.com
Submission Control Number: 259932
Date of Initial Authorization
AUG 10, 2007
Date of Revision:
May 5, 2022
_pms-CLARITHROMYCIN (clarithromycin) _
_Page 2 of 80_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
05/2022
7 WARNINGS AND PRECAUTIONS; 7.1.1 Pregnant Women; 7.1.2 Breast-feeding
05/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
......................................................................................................................4
1.1
Pediatrics
................................................................................................................5
1.2
Geriatrics.................................................................................................................5
2
CONTRAINDICATIONS
.........................................................................................................5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
....................................................................7
4
DOSAGE AND ADMINISTRATION
........................................................................................7
4.1
Dosing Co
                                
                                阅读完整的文件
                                
                            

其他语言的文件

产品特点 产品特点 法文 05-05-2022

搜索与此产品相关的警报